Seven years on, Sanofi’s Dupixent poised to become a blockbuster

Listen to the article
3 minutes

This audio is automatically generated. feedback.

French pharmaceutical company Sanofi is playing the long game with its blockbuster drug Dupixent, and it’s starting to pay off. First approved in 2017 to treat atopic dermatitis, the skin and asthma immunotherapy drug blocks interleukin-4 and interleukin-13, Record sales in second quarter There are some big approvals coming up this year, with more likely to come in the near future.

Pharmaceutical Information Analyst Refers to Dupixent Dupixent, along with GLP-1 weight loss drugs, oncology mainstays, and other immunology drugs such as AbbVie’s Skyries, is one of the “big drugs for big diseases” that could dominate the market by 2030. According to Evaluate, Dupixent’s “pipeline to product” approach could see the treatment exceed $22 billion in sales by the end of the decade.

In its quarterly earnings report, Sanofi said Dupixent sales reached a record $3.6 billion in the second quarter of this year, up more than 29% from the same period last year.

In addition to atopic dermatitis, Dupixent has racked up approvals for asthma, eczema and other skin and infectious diseases. This month, Sanofi and development partner Regeneron won approval in Europe to treat chronic obstructive pulmonary disease, the third-leading cause of death in the world, Brian Ford, head of Sanofi’s specialty care division, said on an earnings call last week. The company is waiting for U.S. approval for COPD by the end of September, but Ford said the asthma experience has given Sanofi the experience to quickly find and treat patients in 2025.

Dupixent’s success has a lot to do with patient demand, Ford said.

“From a patient standpoint, it’s really driven by demand right now,” Ford said. “We’re in a great position not only with the core indications we’ve launched in, but also with the expansion of our core indications across all geographies as we enter new opportunities around the world.”

The race to introduce new treatment options Biologic agents for COPD Competition in the field has also intensified in recent years, and Dupixent could be the first to cross the finish line if it receives FDA approval in September.

Beyond Dupixent, Sanofi is a growing immunology powerhouse, with analysts saying:Underrated.”

Sanofi now expects Dupixent to reach about 13 billion euros ($14 billion) this year, with even bigger gains in sight in 2025 as the COPD engine starts to move and the drug rises to the ranks of Big Pharma’s blockbusters.